Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

Avera and Avera Health Plans transitioned to a new combined patient and member portal as of May 30, 2026. If you haven’t already, create an account and reset your proxy access. Learn how to sign up at Avera.org/MyChart.

Popular Searches

Looking for Something Else?

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (21)
Complete (1)

Showing 1-10 of 21

Sorted By:

A-Z
Z-A

Previous Next

(NSABP B-64) EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
participants planning to undergo chemo for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis
A022102: Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
A042302:Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Ph III Eval of Fixed Duration Zanubrutinib + Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Prev. Untreated Older Pts w/ CLL/SLL
A092205_HNSCC: Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease
PhIII Trial of Pembro vs Pembro/Cetux in Recurrent or Metastatic HN Squamous Cell Carcinoma with Platinum Refractory Disease
C6461003: AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
PH 3 STUDY TO EVAL PF-08634404 IN COMBINATION W/ CHEMOTHERAPY VS BEVACIZUMAB IN COMBINATION W/ CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS W/ METASTATIC COLORECTAL CANCER
CABL001J1US01 (ASC4REAL-2): A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
A Real-world CML Pt Disease Registry to Describe Pt Experience & Clinical Outcomes Among Pts W/ CML Receiving Approved 1st or 2nd Line TKI Therapy
CO46274:A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WITH ENDOCRINE-RESISTANT HORMONE-RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH CHROMOSOME 8P LOSS AND WITHOUT A PIK3CA MUTATION
Phase 2 study evaluating the efficacy and safety of Inavaolisib + Ribociclib + Fulvestrant vs Placebo +Ribociclib + Fulvestrant in Pts with Advanced Breast Cancer
D9803C00001 CLARITY-Gastric02: A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Ph 3 Study of Sonesitatug vedotin in Combination w/Capecitabine w/wo Rilvegostomig in 1st line Claudin18.2-positive,HER2-, Adv/Met Gastric,GEJ,orEsophageal Adenocarcinoma
INCA033890-303: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
A RPhase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With/Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
MK2870-032: A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
Study of sac-TMT for people with (TNBC) or (HR-low positive/HER2 negative) breast cancer who will have surgery to remove their breast cancer.

Previous Next